• Revvity’s new maternal and fetal biochemistry testing platform
• Designed for accessibility, simplicity, and flexibility
• Purpose-built for small to mid-sized labs and clinics to enable this capability in-house for the first time

— Revvity, Inc. announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows.

The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregnancies and is increasing globally due to rising maternal age and conditions such as diabetes and hypertension. Despite international guidelines recommending screening, access has historically been limited to high-throughput centralized laboratories. SuperFlex addresses these gaps by delivering three core advantages:

• Accessible entry — affordable instrument cost with just one annual maintenance, and no reagent wastage even when sample volumes are low
• Operational simplicity — a user-friendly design that minimizes training requirements, to be seamlessly integrated with Revvity’s LifeCycle™ software for streamlined risk assessment and LIMS data transfer
• Flexible throughput — continuous sample loading delivers results in as little as 14 minutes per test, accommodating both urgent and routine workflows

"This SuperFlex offering represents a significant addition to our prenatal portfolio," said Anna Godenhjelm, vice president and general manager of reproductive health at Revvity. "By removing the financial and operational barriers to in-house prenatal screening, we are giving more women access to potentially life-saving testing regardless of where they receive care."

The platform also includes a test menu for both first- and second-trimester biochemical prenatal screening, enabling a versatile, cost-effective, random-access solution well-suited for decentralized testing.

The SuperFlex platform will initially be available in all markets that accept CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.